eClinical Solutions
  • Products
    • Mapper
    • Data Central
    • Clinical Analytics
    • Operational Insights
    • Risk-Based Quality Management
    • Statistical Computing Environment
  • Services
    • Clinical Data Acquisition
    • Clinical Data Management
    • Data Conversion and Standardization
    • Biostatistics and Statistical Programming
    • Functional Service Provider
    • elluminate Implementation
  • Clients
    • For Data Management
    • For Clinical Operations
    • For Medical Monitoring
    • For Biostatistics
    • For R&D IT
    • For Clinical Programming
  • Learn
    • Events
    • elluminate Engage
    • Webinars
    • eClinical Academy
    • Blog
    • Tufts Research
    • Client Stories
    • Videos
    • White Papers
    • Roadmap to Digital Transformation Series
  • About
    • Leadership
    • Careers
    • Partners
    • In the News
    • Press Releases
    • Events
    • Webinars
    • Blog
  • Contact Us
  • Request a Demo
  • Products
      • Platform


      • elluminate Clinical Data Cloud

        One platform for data from ingestion to insights

      • Overview
      • Clients
      • Implementation
      • Trust and Privacy
      • Learn
      • Request a Demo
      • Products


        • Mapper – Map and standardize without programming
        • Data Central – Integrated data review and management
        • Clinical Analytics – Clinical and operational analytics across sources
        • Operational Insights – Manage your trial operations with a data-driven approach
        • Risk-Based Quality Management – Holistic risk management and monitoring
        • Statistical Computing Environment – Accelerate and automate statistical analyses
        • For Every Role


          • Data Management
          • Clinical Operations
          • Medical Monitoring
          • Biostatistics
          • R&D IT
          • Clinical Programming
  • Services
      • Services Approach


      • Clinical Biometrics Services

        Expert biometrics services accelerated by people and technology

      • Overview
      • Clients
      • Products
      • Careers
      • Learn
      • Request a Proposal
      • Services


        • Clinical Data Acquisition – Design and implementation for innovative trials
        • Clinical Data Management – Integrated clinical trial data management services
        • Data Conversion and Standardization – Services streamline data analysis and submission
        • Biostatistics and Statistical Programming – Strategic statistical input and programming
        • Functional Service Provider – Flexible and scalable program-level support
        • elluminate Implementation – Dedicated elluminate enablement and success
        • For Every Role


          • Data Management
          • Clinical Operations
          • Medical Monitoring
          • Biostatistics
          • R&D IT
          • Clinical Programming
        • Urovant Integrated Summary of Safety (ISS) Case Study – Urovant streamlines ISS submission prep and planning with eClinical Solutions’ biostatistics and statistical programming services and elluminate
        • View case study
  • Clients
      • Clients


      • Powering Life Science Innovators

        Helping clients digitize and transform clinical data

      • See all
      • Products
      • Services
      • About eClinical
      • Learn
      • Request a Demo
        • Customer Stories


        • Agios Pharmaceuticals
        • bluebird bio
        • Bristol Myers Squibb
        • Cerevel
        • See All
        • Partners


        • eClinical Partners
        • For Every Role


          • Data Management
          • Clinical Operations
          • Medical Monitoring
          • Biostatistics
          • R&D IT
          • Clinical Programming
        • BMS elluminate Clinical Data Cloud Case Study – BMS adopts a unified clinical data architecture with the elluminate Clinical Data Cloud as the foundation for data access across sources
        • View case study
  • Learn
      • Learn


      • Digital Clinical Learning Center

        The latest resources to help you solve data challenges

      • See all
      • Products
      • Services
      • Clients
      • About eClinical
      • Request a Demo
        • Events and Webinars


        • Events
        • elluminate Engage
        • Webinars
        • eClinical Academy
        • Resources


        • Blog
        • Tufts Research
        • Client Stories
        • Videos
        • White Papers
        • Roadmap to Digital Transformation Series
        • See All
        • For Every Role


          • Data Management
          • Clinical Operations
          • Medical Monitoring
          • Biostatistics
          • R&D IT
          • Clinical Programming
        • eClinical Solutions Blog – Stay up to date with the latest posts and perspectives to help guide your digital data transformation strategies
        • Read the blog
  • About
      • About


      • Leading the eClinical Evolution

        Experienced life science leaders driving data innovation

      • Learn more
        • Company


        • Leadership
        • Careers
        • Partners
        • News


        • In the News
        • Press Releases
        • Events
        • Webinars
        • Blog
        • Connect


          • Contact Us
        • Careers at eClinical Solutions – Accelerate your career, shape the future of life sciences and make your contribution to helping bring therapies to patients faster
        • Learn more
  • Request a Demo
  • Contact Us

Understanding Risk-Based Quality Management (RBQM)

Author: eClinical Solutions
Published: August 10, 2022 | 5 min read
Share:

Ensuring patient safety is a critical objective across all clinical studies. To keep participants safe while simultaneously keeping clinical trials on track, proactive monitoring and early detection of potential risk play key roles in the drug development process. Initial guidance from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for adopting a risk-based approach to clinical trial monitoring was released almost 10 years ago. The FDA and EMA continue to press the industry to meet the guidance objectives. This guidance, in addition to continuous updates to The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) standards around total quality management objectives, have caused risk-based monitoring (RBM) to become a more common practice across all clinical trials.

In recent years, the adoption of decentralized trial (DCT) models has created both opportunities and challenges in clinical development. While DCT models make clinical studies more accessible and relieves patient burden, the volume and variety of study data collected adds greater complexity to trial management and monitoring processes.

One strategy to address the increasing complexity of trial monitoring is to evolve from RBM to Risk-based Quality Management (RBQM) — which is an end-to-end process that begins with protocol design and focuses on factors critical to quality throughout the trial lifecycle. Our latest white paper highlights why the industry is moving towards RBQM and how sponsors can build a scalable approach that protects trial participants, helps manage risks, upholds study integrity, and increases operational efficiencies.

Understanding Risk-Based Quality Management

How Does RBQM Differ from RBM?

Risk-based monitoring (RBM) and Risk-based quality management (RBQM) share a similar focus on identifying and mitigating potential risks. Where RBM and RBQM differ is in how widely they are applied in a trial.

RBM is a piece of an overarching RBQM strategy and while RBM uses advancements in technology and analytics to track and predict risks, RBQM is a more expansive process. Focusing on factors critical to trial quality, RBQM begins at the time of protocol design — so that mitigation can be built into the protocol and other trial documents — and identifies risk on an ongoing basis for the duration of the trial. In today’s evolving clinical trial landscape, a clinical trial often includes millions of data points, making RBQM more essential than ever before. When sponsors leverage this end-to-end methodology, trial participant risk is reduced, and costly downstream issues are avoided.

Current State of RBQM Adoption in the Market

Over the last two years, the life sciences industry has seen a dramatic acceleration in digitization and technology adoption, especially in clinical development. The industry has embraced numerous technical capabilities such as decentralized trial platforms and RBQM software solutions that had been “emerging” for many years and are now becoming mainstream.  

The Gartner 2022 Hype Cycle for Life Science Clinical Development — which explores areas of innovation that will enable life sciences organizations to respond to industry challenges — recently highlighted this trend. In this report, risk-based and central monitoring approaches were classified as “on the Slope of Enlightenment.” This classification indicates that over the next two to five years, the implementation and expansion of RBQM practices by sponsors will gain increasing momentum as digital transformation continues, driving the need for more advanced RBQM technology and strategies to support innovation and the adoption of these approaches.

Drivers for RBQM Adoption Across Clinical Trials

While RBM adoption within the drug development industry has been on the rise for years, regulatory and external factors are driving life sciences organizations to take it a step further and evolve from RBM to RBQM in order to meet the demands of more adaptive and digital clinical trials.

Risk-based monitoring started to gain traction in 2013 when the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) released guidance for adopting risk-based approaches for more efficient trial monitoring. In 2016, The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) released ICH E6 (R2), requiring sponsors to develop risk-based methods to assess and manage trial risk. Following that, the FDA placed ICH E6 (R2) as a revision to Good Clinical Practice (GCP) in the federal registry. The third revision to ICH E6 is expected in 2022 and will focus on risk-based approaches and the concept of quality by design while acknowledging the diversity of trial design, data sources, and different contexts in which clinical trials can be conducted. Additionally, RBM guidance and approach documents released by pre-competitive alliances such as TransCelerate BioPharma have helped to further drive the adoption of risk-based approaches. 

The Covid-19 pandemic has been an undeniable force in bringing sweeping changes to the way clinical research is conducted. Most significantly, the pandemic has been a catalyst for moving away from inefficient practices and pushing new clinical trial execution models to become standard practice. With remote and virtual monitoring approaches becoming mainstream, many organizations were forced to prioritize risk-based approaches, further accelerating the initiatives set in motion by ICH E6 (R2). The pandemic has proved that the drug development industry can no longer rely on inefficient trial execution models and must instead pivot to approaches that prioritize proactive risk assessment and mitigation.

Furthermore, these drivers for adoption are impacting both insourced and outsourced trial models. Emerging and mid-size sponsors working in outsourced models are adopting RBQM at an increasing rate. Using RBQM technology and methodology in an outsourced model enables sponsors to take a data-driven approach to overall risk assessment and analysis, creating additional value to supplement a CRO’s oversight strategy. Read this white paper to explore how you can implement a holistic RBQM strategy to ensure quality throughout the clinical trial lifecycle.

Access the White Paper

Blog
RBQM

Related Content

Taking a Proactive Approach to RBQM Adoption

Posted in: Blog

Four Key Elements of a Risk-Based Approach

Posted in: Blog

Establishing a Foundation for a Holistic RBQM Strategy

Posted in: White Papers

Recent Blog Posts

Driving Quality and Speed in Clinical Data Acquisition

Ten Years of eClinical: 10 Predictions for 2023 and Beyond

Ten Years of eClinical: 10 Key Company Milestones

  • Products
  • Mapper
  • Data Central
  • Clinical Analytics
  • Operational Insights
  • Risk-Based Quality Management
  • Statistical Computing Environment
  • Services
  • Clinical Data Acquisition
  • Clinical Data Management
  • Data Conversion and Standardization
  • Biostatistics and Statistical Programming
  • Functional Service Provider
  • elluminate Implementation
About & Resources
  • Clients
  • Learn
  • Events
  • About
  • Leadership
  • Press Releases
  • Careers
  • Partners
  • Contact Us
  • Support

Subscribe to eClinical Insights and News

Get data strategy resources delivered to your inbox

We’re committed to your privacy. eClinical Solutions uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

  • LinkedIn
  • Twitter
  • YouTube

© eClinical Solutions LLC. All rights reserved. elluminate® is a registered service mark of eClinical Solutions LLC.

  • Privacy Policy
  • Trust and Privacy
  • Legal
  • Contact Us

Upcoming Webinar:
The Foundation of Your Digital Trials

Register Now
X
Scroll Up